Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Positron-emission tomography monitoring of anti-glioblastoma HSV-1-tk gene therapy

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

A phase I/II clinical trial of gene therapy for recurrent glioblastoma has been initiated in which non-invasive monitoring of the critical steps is performed by a combination of standard clinical positron-emission tomography (PET) for metabolic identification/evaluation of malignant lesions with pioneering PET imaging of HSV-1-tk transgene expression. Localization, characterization and trial follow-up of target tumors rely on multitracer PET brain imaging probed with radiolabeled 2-[18F]fluoro-2-deoxy-D-glucose (FDG), methyl-[11C]-L-methionine (MET) and 3´-deoxy-3´-[18F]fluoro-L-thymidine (FLT) while the location, magnitude and duration of therapeutic HSV-1-tk transgene expression is monitored with 2´-fluoro-2´-deoxy-1-β-D-arabinofuranosyl-5-[124I]iod ([124I]-FIAU). In addition, in order to improve the distribution of the vector within the tumor tissue, a stereotactically guided convection-enhanced delivery (CED) protocol was devised in which the transfection of the HSV-1-tk gene into brain tumor cells is mediated by a liposome-DNA complex. Preliminary findings on a first group of five patients demonstrated that FIAU-PET imaging of HSV-1-tk expression in patients with glioblastoma is feasible and that vector-mediated gene expression may predict the therapeutic effect of ganciclovir prodrug activation. In addition, they showed that integration of magnetic resonance (MR) and PET imaging data into a 3D stereotaxic coordinate system results in an efficient non-invasive spatio-temporal monitoring of a brain gene therapy trial. Such a non-invasive imaging provides the means to identify potential critical parameters and to implement dosing/ routing adjustments that will have a critical impact on the development of standardized gene therapy protocols.


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation